[Consensus statement on inhaled recombinant human granulocyte-macrophage colony-stimulating factor for autoimmune pulmonary alveolar proteinosis (2022)].

Abstract

Autoimmune pulmonary alveolar proteinosis (aPAP) is the most common(around 90%) type of pulmonary alveolar proteinosis, characterized by the presence of granulocyte-macrophage colony-stimulating factor (GM-CSF) autoantibody. Accumulating evidence has demonstrated the effectiveness of inhaled recombinant human GM-CSF for aPAP. Such a therapy has not been approved in China yet and has been classified off-label and unusual route of administration. Our expert consensus group evaluated the current knowledge with the methods of grading of recommendation assessment, development and evaluation (GRADE). The current evidence-based consensus statement covers the suitable population for inhaled GM-CSF therapy, details of prescription, usage during pregnancy and lactation, adverse effects and other suggestions in clinical usage. This consensus statement provides a clinical practice guideline of inhaled GM-CSF for aPAP in China and hopefully will accelerate basic and clinical research of aPAP.

• Authors: Expert Consensus Group of Pulmonary Alveolar Proteinosis, Rare Lung Disease Alliance, China Alliance of Rare Diseases
• Journal: Zhonghua jie he he hu xi za zhi = Zhonghua jiehe he huxi zazhi = Chinese journal of tuberculosis and respiratory diseases (Zhonghua Jie He He Hu Xi Za Zhi) Vol. 45 Issue 9 Pg. 865-871 (Sep 12 2022) ISSN: 1001-0939 [Print] China
• PMID: 36097923 (Publication Type: Journal Article)

Chemical References

• Granulocyte-Macrophage Colony-Stimulating Factor

Topics

• Female
• Humans
• Administration, Inhalation
• Autoimmune Diseases
• Granulocyte-Macrophage Colony-Stimulating Factor (therapeutic use)
• Pulmonary Alveolar Proteinosis (drug therapy)